The drama continues over Pfizer's deal for Wyeth. This Review & Outlook opinion piece from the Wall Street Journal doesn't mince words about the situation, starting off with this: "Emergency is too strong a word for Pfizer's $68 billion agreement to buy Wyeth, but not by much. The deal shows the afflictions that beset the larger American pharmaceutical industry, which ought to concern anyone who cares about U.S.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

The New York Times reports on a project to develop a tree DNA database to uncover instances of illegal logging.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.